Serial Body Composition Measurements by PEAPOD (SBMP)
Body Composition at Birth and Its Evolution Over the First 6 Months in Neonates Using Air-displacement Plethysmography (PEAPOD Machine): A Prospective Longitudinal Matched Case-control Study in a Low-income Setting
Birth weight alone is not precise enough to explain the nutritional status of a newborn baby. For SGA babies (born smaller than they should be for birth age and sex) a sophisticated machine called a PEAPOD can calculate the percentage of body fat, fat mass and fat-free mass. The PEAPOD does these measurements by moving air around a baby placed on a scale inside a Pod. The procedure is quick (average 7 minutes), accurate, safe and useful to 6 months of age. The investigators want to understand if there are clues in the body composition of babies born to small compared to babies of the right size that point to why born too small have increased risk of heart and blood vessel problems linked to issues like diabetes and obesity, later in life. A type of study called "matched case-control" could help us investigate mother factors that are associated with being born too small. Cases (SGA) will be matched with controls (AGA, a baby born not too small and not too large) based on sex, weeks of age at birth (±1 week), number of births the mother has had (same parity). Information about the study will be given in pregnancy. If consent is provided blood samples (mother and cord) will be collected at birth. Small amount of blood will be taken from mother and baby one time at birth, 1, 2, 3, 4, 5 and 6 months; and babies will attend for 7 PEAPOD measurements unless birth weight >6.0kg is reached first. Additionally, mother's breast milk will be collected. These will be used to measure different molecules in the blood related to health and disease. With the data from this study, the investigators may be able to provide better recommendations during pregnancy that can help optimize baby and infant nutritional status and adult health outcomes.
調査の概要
詳細な説明
This study aims to investigate body composition at birth and its evolution over the first six months of life in neonates using air-displacement plethysmography (PEAPOD). Traditional anthropometric measures such as birth weight and length provide limited information on neonatal nutritional status, as they do not distinguish between fat mass and fat-free mass. Understanding early body composition may offer important insights into infant growth patterns and long-term health outcomes, including risks of metabolic and cardiovascular diseases.
This is a prospective longitudinal matched case-control study conducted at the Mawker Thai Clinic, Shoklo Malaria Research Unit (SMRU), along the Thailand-Myanmar border. The study will recruit 300 mother-infant pairs, including 150 small-for-gestational-age (SGA) neonates and 150 appropriate-for-gestational-age (AGA) neonates. Cases and controls will be matched based on sex, gestational age (±1 week), and parity.
Following informed consent obtained during pregnancy, baseline maternal data will be collected from routine antenatal care. After delivery, neonatal eligibility will be confirmed, and study procedures will begin within 24-48 hours of birth. Body composition measurements will be performed using the PEAPOD device, a validated, non-invasive method for assessing fat mass, fat-free mass, and percentage body fat in infants.
Participants will be followed monthly up to six months postpartum (or until the infant reaches 6.0 kg, the upper limit for PEAPOD measurement). At each visit, both maternal and infant assessments will be conducted. These include anthropometric measurements, body composition assessments, and collection of biological samples such as maternal venous blood, umbilical cord blood, capillary blood samples, and maternal breast milk. Laboratory analyses will include haematological parameters and nutritional biomarkers relevant to maternal and infant health.
The primary objective is to compare longitudinal changes in body composition between SGA and AGA infants during the first six months of life. Secondary objectives include identifying maternal and fetal factors associated with neonatal and infant body composition, including maternal nutritional status, gestational weight gain, metabolic conditions, and breast milk composition.
This study will provide important evidence on early-life body composition trajectories in a resource-limited setting and may inform strategies to improve maternal and infant health, nutritional interventions, and long-term disease prevention.
研究の種類
入学 (推定)
連絡先と場所
研究連絡先
- 名前：Dr Nay Win Tun, MBBS
- 電話番号：+66800273370
- メール：naywintun@shoklo-unit.com
研究連絡先のバックアップ
- 名前：Htet Htet Aung, BA
- 電話番号：+66828082412
- メール：htethtetaung@tropmedres.ac
研究場所
-
-
Changwat Tak
-
Tak、Changwat Tak、タイ
- Mawker Thai Clinic, Shoklo Malaria Research Unit (SMRU)
-
コンタクト：
- Dr Nay Win Tun, MBBS
- 電話番号：+66800273370
- メール：naywintun@shoklo-unit.com
-
主任研究者：
- Prof Rose McGready
-
副調査官：
- Prof Francois H. Nosten
-
副調査官：
- Dr Sue J Lee
-
副調査官：
- Dr Nay Win Tun
-
副調査官：
- Dr Aung Myat Min
-
副調査官：
- Dr Mellie Gilder
-
副調査官：
- Dr May Thu Thu Aung
-
副調査官：
- Dr Ajjima Thussachan
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
Pregnant woman attending for antenatal care or admitted for delivery and their neonates attending at Mawker Thai clinic along the Thailand-Myanmar border. The study population includes both small for gestational age (SGA) and appropriate for gestational age (AGA) neonates and their mothers, representing a resource-limited border population.
説明
Inclusion Criteria:
Pregnant woman
- The pregnant woman who had received a good dating ultrasound scan less than 24 weeks' gestation and maternal age would be ≥ 18 years old.
- Willing and able to provide informed consent.
- Able to attend monthly follow-up visits.
Neonates
-
Normal, single-baby pregnancy (singleton) born at term at Mawker Thai clinic.
- Neonate eligibility can only be confirmed after delivery.
Exclusion Criteria:
Pregnant woman
-
Families residing far from the study site and unable to commit to follow-up. Neonates*
-
Baby born requiring admission to the special care baby unit (SCBU).
- Neonate eligibility can only be confirmed after delivery.
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 観測モデル：CASE_CONTROL
- 時間の展望：PROSPECTIVE
コホートと介入
グループ/コホート |
介入・治療 |
|---|---|
|
Small for Gestational Age (SGA) Neonates
Neonates classified as small for gestational age (SGA), defined as birth weight below the 10th percentile for gestational age. Participants will undergo non-invasive body composition measurements using air-displacement plethysmography (PEAPOD) and follow-up assessments at monthly intervals up to six months of age (or until reaching 6.0 kg). Additional study procedures include anthropometric measurements and collection of biological samples (maternal blood, cord blood, infant capillary blood, and breast milk) for laboratory analyses. |
The PEAPOD air displacement plethysmography system is a non-invasive device used to measure infant body composition, including fat mass, fat-free mass, and percentage body fat. The measurement is performed by placing the infant in a calibrated chamber for a short duration, during which body volume and mass are assessed. The procedure is safe, painless, and does not involve radiation or invasive techniques. In this study, the device is used solely for observational measurement of body composition and not as a therapeutic intervention.
他の名前：
|
|
Appropriate for Gestational Age (AGA) Neonates
Neonates classified as appropriate for gestational age (AGA), defined as birth weight between the 10th and 90th percentile for gestational age. Participants will undergo the same study procedures as the SGA group, including non-invasive body composition measurements using PEAPOD and follow-up assessments at monthly intervals up to six months of age (or until reaching 6.0 kg), along with anthropometric measurements and collection of biological samples for laboratory analyses. |
The PEAPOD air displacement plethysmography system is a non-invasive device used to measure infant body composition, including fat mass, fat-free mass, and percentage body fat. The measurement is performed by placing the infant in a calibrated chamber for a short duration, during which body volume and mass are assessed. The procedure is safe, painless, and does not involve radiation or invasive techniques. In this study, the device is used solely for observational measurement of body composition and not as a therapeutic intervention.
他の名前：
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Body composition changes - Fat mass in neonates with small for gestational age (SGA) and appropriate for gestational age (AGA) at birth and during the first 6 months of life
時間枠：At birth, 1, 2, 3, 4, 5 and 6 months of life (unless body weight >6.0kg is reached first)
|
Fat mass (kg) measured using air displacement plethysmography (PEAPOD) at birth and during follow-up visits to compare between small for gestational age (SGA) and appropriate for gestational age (AGA) infants |
At birth, 1, 2, 3, 4, 5 and 6 months of life (unless body weight >6.0kg is reached first)
|
|
Body composition changes - Fat-free mass in neonates with small for gestational age (SGA) and appropriate for gestational age (AGA) at birth and during the first 6 months of life
時間枠：At birth, 1, 2, 3, 4, 5 and 6 months of life (unless body weight >6.0kg is reached first)
|
Fat-free mass (kg) measured using PEAPOD at birth and during follow-up visits to compare between SGA and AGA infants |
At birth, 1, 2, 3, 4, 5 and 6 months of life (unless body weight >6.0kg is reached first)
|
|
Percentage body fat in SGA and AGA infants
時間枠：At birth, 1, 2, 3, 4, 5 and 6 months of life (unless body weight >6.0kg is reached first)
|
Percentage body fat (%) measured using PEAPOD at birth and during follow-up visits to compare between SGA and AGA infants |
At birth, 1, 2, 3, 4, 5 and 6 months of life (unless body weight >6.0kg is reached first)
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Maternal First-Trimester Body Mass Index (BMI)
時間枠：Baseline (antenatal records)
|
Maternal first-trimester BMI (kg/m²) calculated from weight and height recorded during antenatal care |
Baseline (antenatal records)
|
|
Maternal Gestational Weight Gain
時間枠：Baseline (antenatal records)
|
Maternal gestational weight gain (kg) calculated from antenatal weight measurements |
Baseline (antenatal records)
|
|
Gestational Diabetes Mellitus Status
時間枠：Baseline (antenatal records)
|
Presence or absence of gestational diabetes mellitus documented in maternal clinical records |
Baseline (antenatal records)
|
|
Maternal Anaemia
時間枠：Baseline to maximum 6 months postpartum
|
Presence or absence of maternal anaemia determined from maternal haemoglobin measurements |
Baseline to maximum 6 months postpartum
|
|
Maternal HbA1c Concentration
時間枠：Delivery and 2 months postpartum
|
Maternal glycated haemoglobin (HbA1c) percentage (%) measured from maternal blood samples |
Delivery and 2 months postpartum
|
|
Breast Milk Creamatocrit
時間枠：At birth to maximum 6 months postpartum
|
Creamatocrit percentage (%) measured from maternal breast milk samples |
At birth to maximum 6 months postpartum
|
|
Breast Milk Sodium Concentration
時間枠：At birth to maximum 6 months postpartum
|
Sodium concentration (mmol/L) measured from maternal breast milk samples |
At birth to maximum 6 months postpartum
|
|
Breast Milk Proteomic Profile
時間枠：Delivery and monthly postpartum until 6 months
|
Proteomic profile of maternal breast milk measured using MALDI-TOF analysis |
Delivery and monthly postpartum until 6 months
|
協力者と研究者
捜査官
- 主任研究者：Prof Rose McGready、Shoklo Malaria Research Unit
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
その他の研究ID番号
- SBMP
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Individual participant data (IPD), including de-identified clinical, anthropometric, laboratory, and body composition data collected during the study, will not be made publicly available. Data collected in this study involve sensitive information from mothers and neonates in a vulnerable population, and sharing will be restricted to protect participant confidentiality. De-identified data may be made available upon reasonable request, subject to review and approval by the study investigators and relevant institutional authorities, and in accordance with data sharing agreements and applicable ethical and regulatory requirements.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。